Designing cell lines for viral vaccine production: Where do we stand?

Biotechnology Journal

Volumn 10, Issue 5, 2015, Pages 728-740

  Genzel, Yvonne ^a  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

Author keywords

Adaptation to suspension growth; Cell line screening; Cell substrates; Designer cells; Viral vaccine production

Indexed keywords

ANIMALS; ANTIBODIES; BIOREACTORS; CELL CULTURE; CYTOLOGY; DESIGN; MONOCLONAL ANTIBODIES; SUBSTRATES; VACCINES;

CELL LINES; CELL SUBSTRATES; CHEMICALLY DEFINED MEDIAS; CHINESE HAMSTER OVARY CELLS; DISPOSABLE BIOREACTORS; MADIN-DARBY CANINE KIDNEYS; MONOCLONAL ANTIBODY PRODUCTION; VACCINE PRODUCTION;

CELLS;

CARCINOGEN; MONOCLONAL ANTIBODY; VIRUS VACCINE;

ADAPTATION; ADENOVIRIDAE; AGE1.CR CELL LINE; ANTIBODY PRODUCTION; BHK21 CELL LINE; BIOREACTOR; CAP CELL LINE; CEF CELL LINE; CELL GROWTH; CELL IMMORTALIZATION; CELL LINE; CELL SUSPENSION; CHICKEN EMBRYO CELL LINE; CHO CELL LINE; CULTURE MEDIUM; DNA TUMOR VIRUS; EB66 CELL LINE; FISH CELL LINE; FREEZE THAWING; HEK293 CELL LINE; HERPES SIMPLEX VIRUS; HKB11 CELL LINE; HOST CELL; HUMAN; HUMAN LIVER CELL LINE; INFLUENZA VIRUS; MDCK CELL LINE; MEASLES VIRUS; MRC5 CELL LINE; NONHUMAN; PER.C6 CELL LINE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; QOR/2E11 CELL LINE; REVIEW; ROTAVIRUS; SCALE UP; SCREENING; SIMIAN VIRUS 40; SOGE CELL LINE; ULTRAVIOLET IRRADIATION; VACCINE PRODUCTION; VERO CELL LINE; WEST NILE FEVER; WI38 CELL LINE; ANIMAL; BATCH CELL CULTURE; BIOSYNTHESIS; CRICETULUS; PROCEDURES; VIROLOGY; VIRUS CULTURE;

ANIMALIA; CRICETULUS GRISEUS;

ANIMALS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CELL LINE; CRICETULUS; HUMANS; VIRAL VACCINES; VIRUS CULTIVATION;

EID: 84928827461     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400388     Document Type: Review

References (94)

1. Merten, O.-W., Bakker, W. A. M., Vorlop, J., Reiter, M. et al., Virus production under suspension conditions, in: Meyer, H.-P., Schmidhalter, D. R. (Eds.), Industrial scale suspension culture of living cells, Wiley Blackwell 2014, pp. 503-554.
2. Botezatu, L., Sievers, S., Gama-Norton, L., Schucht, R. et al., Genetic aspects of cell line development from a synthetic biology perspective. Adv. Biochem. Eng. Biotechnol. 2012, 127, 251-284.
3. Alldread, R. M., Birch, J. R., Metcalfe, H. K., Farid, S. et al., Large scale suspension culture of mammalian cells, in: Meyer, H.-P., Schmidhalter, D. R. (Eds.), Industrial scale suspension culture of living cells, Wiley Blackwell 2014, pp. 411-462.
4. MacDonald, C., Development of new cell lines for animal cell biotechnology. Crit. Rev. Biotechnol. 1990, 10, 155-178.
5. Knezevic, I., Stacey, G., Petricciani, J., Sheets, R., Substrates, W. H. O. S. G. o. C., Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA. Biologicals 2010, 38, 162-169.
6. Graham, F. L., Smiley, J., Russell, W. C., Nairn, R., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59-74.
7. Louis, N., Evelegh, C., Graham, F. L., Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 1997, 233, 423-429.
8. Shaw, G., Morse, S., Ararat, M., Graham, F. L., Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002, 16, 869-871.
9. Betakova, T., Svetlikova, D., Gocnik, M., Overview of measles and mumps vaccine: origin, present, and future of vaccine production. Acta virologica 2013, 57, 91-96.
10. Genzel, Y., Behrendt, I., Konig, S., Sann, H., Reichl, U., Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 2004, 22, 2202-2208.
11. Auslander, S., Fussenegger, M., From gene switches to mammalian designer cells: present and future prospects. Trends Biotechnol. 2013, 31, 155-168.
12. Jordan, I., Vos, A., Beilfuss, S., Neubert, A. et al., An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27, 748-756.
13. Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J. et al., New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 1998, 9, 1909-1917.
14. Gregersen, J. P., Schmitt, H. J., Trusheim, H., Broker, M., Safety of MDCK cell culture-based influenza vaccines. Future Microbiol. 2011, 6, 143-152.
15. Groener, A., Vorlop, J., Animal cells and processes for the replication of influenza viruses. WO Patent 9737000, 1997.
16. Donis, R. O., The Influenza Cell Culture Working Group, Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 2014, 32, 6583-6590.
17. Haredy, A. M., Takenaka, N., Yamada, H., Sakoda, Y. et al., An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice. Clin. Vaccine Immunol. CVI 2013, 20, 998-1007.
18. Hess, R. D., Weber, F., Watson, K., Schmitt, S., Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012, 30, 2715-2727.
19. Jayesh, P., Seena, J., Singh, I. S., Establishment of shrimp cell lines: perception and orientation. Indian J. Virol. 2012, 23, 244-251.
20. Plachy, J., Hejnar, J., Chicken cells-oncogene transformation, immortalization and more. Folia Biol. (Praha) 2002, 48, 126-138.
21. Fukuma, A., Yoshikawa, R., Miyazawa, T., Yasuda, J., A new approach to establish a cell line with reduced risk of endogenous retroviruses. PloS one 2013, 8, e61530.
22. Pentel, P. R., LeSage, M. G., New directions in nicotine vaccine design and use. Adv. Pharmacol. 2014, 69, 553-580.
23. Swiech, K., Picanco-Castro, V., Covas, D. T., Human cells: new platform for recombinant therapeutic protein production. Protein Expr. Purif. 2012, 84, 147-153.
24. Hay, R. J., Human cells and cell cultures: availability, authentication and future prospects. Hum. Cell 1996, 9, 143-152.
25. Stepanenko, A. A., Kavsan, V. M., Immortalization and malignant transformation of eukaryotic cells. Tsitol Genet. 2012, 46, 36-75.
26. Khoobyarian, N., Marczynska, B., Cell immortalization: the role of viral genes and carcinogens. Virus Res. 1993, 30, 113-128.
27. Hopfer, U., Jacobberger, J. W., Gruenert, D. C., Eckert, R. L. et al., Immortalization of epithelial cells. Am. J. Physiol. 1996, 270, C1-11.
28. Lipps, C., May, T., Hauser, H., Wirth, D., Eternity and functionality - rational access to physiologically relevant cell lines. Biol. Chem. 2013, 394, 1637-1648.
29. Levine, A. J., The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009, 384, 285-293.
30. Kraus, B., von Fircks, S., Feigl, S., Koch, S. M. et al., 22nd European Society for Animal Cell Technology (ESACT), Meeting on Cell Based Technologies, BMC Proceedings, Vienna, 2011.
31. Ogura, H., Fujiwara, T., Establishment and characterization of a virus-free chick cell line. Acta Med. Okayama 1987, 41, 141-143.
32. Coussens, P. M., Smith, K. A., Weber, P. S., Colvin, C. J., Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production. Vaccine 2011, 29, 8661-8668.
33. Jaiswal, A. S., Multani, A. S., Pathak, S., Narayan, S., N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol. Cancer 2004, 3, 3.
34. Genzel, Y., Rodig, J., Rapp, E., Reichl, U., Vaccine production: Upstream processing with adherent or suspension cell lines. Methods Mol. Biol. 2014, 1104, 371-393.
35. Genzel, Y., Vogel, T., Buck, J., Behrendt, I. et al., High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014, 32, 2770-2781.
36. Kuczewski, M., Schirmer, E., Lain, B., Zarbis-Papastoitsis, G., A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnol. J. 2011, 6, 56-65.
37. Sinacore, M. S., Drapeau, D., Adamson, S. R., Adaptation of mammalian cells to growth in serum-free media. Mol. Biotechnol. 2000, 15, 249-257.
38. Jordan, I., Horn, D., John, K., Sandig, V., A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium. Viruses 2013, 5, 321-339.
39. Moss, B., Poxvirus entry and membrane fusion. Virology 2006, 344, 48-54.
40. Sandig, V., Jordan, I., Cell Line for Propagation of Highly Attenuated AlphaViruses. US Patent 229969 A1, 2011.
41. Frensing, T., Pflugmacher, A., Bachmann, M., Peschel, B., Reichl, U., Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production. Appl. Microbiol. Biotechnol. 2014, 98, 8999-9008.
42. Frensing, T., Heldt, F. S., Pflugmacher, A., Behrendt, I. et al., Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles. PloS one 2013, 8, e72288.
43. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A. et al., Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 1996, 7, 215-222.
44. Pau, M. G., Ophorst, C., Koldijk, M. H., Schouten, G. et al., The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19, 2716-2721.
45. Lewis, J. A., Brown, E. L., Duncan, P. A., Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. biol. 2006, 123, 165-176; discussion 183-197.
46. Houspie, L., Keyaerts, E., Maes, P., Van Ranst, M., Susceptibility of the PER.C6 cell line for infection with clinical human respiratory syncytial virus isolates. J. Virol. Methods 2012, 181, 37-42.
47. Verschuur, M., Yallop, C. A., Meijer, J., Scalable process for culturing PER.C6 cells and producing products therefrom. WO Patent 006989 A1, 2010.
48. Berdichevsky, M., Gentile, M. P., Hughes, B., Meis, P. et al., Establishment of higher passage PER.C6 cells for adenovirus manufacture. Biotechnol. Prog. 2008, 24, 158-165.
49. Yallop, C., Crowley, J., Cote, J., Hegmans-Brouwer, K. et al., PER.C6 cells for the manufacture of biopharmaceutical proteins, in: Knäblein, J. (Ed.), Modern biopharmaceuticals / 3., Weinheim: Wiley-VCH, 2005.
50. Luitjens, A., Herman Van, H., Method for the production of ad26 adenoviral vectors. WO Patent 098592 A1, 2011.
51. Schiedner, G., Hertel, S., Kochanek, S., Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum. Gene Ther. 2000, 11, 2105-2116.
52. Genzel, Y., Behrendt, I., Rodig, J., Rapp, E. et al., CAP, a new human suspension cell line for influenza virus production. Appl. Microbiol. Biotechnol. 2013, 97, 111-122.
53. Vlecken, D. H., Pelgrim, R. P., Ruminski, S., Bakker, W. A., van der Pol, L. A., Comparison of initial feasibility of host cell lines for viral vaccine production. J. Virol. Methods 2013, 193, 28-41.
54. Sandig, V., Jordan, I., Brundke, E., Productivity augmenting protein factor, novel cell lines and uses thereof. US Patent 164727 A1, 2012.
55. Jordan, I., Sandig, V., Specific and persistent activation of heat shock response in cell lines using a viral factor. WO Patent 078928 A2, 2010.
56. Jordan, I., Northoff, S., Thiele, M., Hartmann, S. et al., A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39, 50-58.
57. Lohr, V., Hadicke, O., Genzel, Y., Jordan, I. et al., The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis. BMC Biotechnol. 2014, 14, 72.
58. Brown, S. W., Mehtali, M., The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production. PDA J. Pharm. Sci. Technol. 2010, 64, 419-425.
59. Olivier, S., Jacoby, M., Brillon, C., Bouletreau, S. et al., EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. mAbs 2010, 2, 405-415.
60. Guehenneux, F., Moreau, K., Magali, E., Mehtali, M., Duck embryonic derived stem cell lines for the production of viral vaccines. European Patent Application EP1985305 A1, 2008.
61. Guehenneux, F., Pain, B., Production of poxviruses with adherent or non adherent avian cell lines. US Patent 233834 A1, 2006.
62. Mehtali, M., Champion-Arnaud, P., Arnaud, L., Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines. US Patent 081251 A1, 2009.
63. Pain, B., Guehenneux, F., Avian cell lines for the production of useful substances. WO Patent 03076601 A1, 2003.
64. Smith, K. A., Colvin, C. J., Weber, P. S., Spatz, S. J., Coussens, P. M., High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 2008, 26, 3778-3782.
65. Lee, J., Foster, D. N., Bottje, W. G., Jang, H. M. et al., Establishment of an immortal chicken embryo liver-derived cell line. Poult. Sci. 2013, 92, 1604-1612.
66. Kambara, H., Fukuhara, T., Shiokawa, M., Ono, C. et al., Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J. Virol. 2012, 86, 1382-1393.
67. Lu, J., Xiang, Y., Tao, W., Li, Q. et al., A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate. J. Virol. 2014, 88, 1484-1491.
68. Shiokawa, M., Fukuhara, T., Ono, C., Yamamoto, S. et al., Novel permissive cell lines for complete propagation of hepatitis C virus. J. Virol. 2014, 88, 5578-5594.
69. Reiter, M., Mundt, W., Feigl, S., von Fricks, S., Method for producing continuous cell lines AU2013206102 A1, 2013.
70. Schumacher, D., Tischer, B. K., Teifke, J. P., Wink, K., Osterrieder, N., Generation of a permanent cell line that supports efficient growth of Marek's disease virus (MDV) by constitutive expression of MDV glycoprotein E. J. Gen. Virol. 2002, 83, 1987-1992.
71. Sommerset, I., Krossoy, B., Biering, E., Frost, P., Vaccines for fish in aquaculture. Expert Rev. Vaccines 2005, 4, 89-101.
72. Dong, C., Weng, S., Shi, X., Xu, X. et al., Development of a mandarin fish Siniperca chuatsi fry cell line suitable for the study of infectious spleen and kidney necrosis virus (ISKNV). Virus Res. 2008, 135, 273-281.
73. Dong, C., Shuang, F., Weng, S., He, J., Cloning of a new fibroblast cell line from an early primary culture from mandarin fish (Siniperca chuatsi) fry for efficient proliferation of megalocytiviruses. Cytotechnology 2013, 6, 883-890.
74. Sarath Babu, V., Abdul Majeed, S., Nambi, K. S., Taju, G. et al., Comparison of betanodavirus replication efficiency in ten Indian fish cell lines. Arch. Virol. 2013, 158, 1367-1375.
75. Lakra, W. S., Swaminathan, T. R., Rathore, G., Goswami, M. et al., Development and characterization of three new diploid cell lines from Labeo rohita (Ham.). Biotechnol. Prog. 2010, 26, 1008-1013.
76. Lopez-Doriga, M. V., Smail, D. A., Smith, R. J., Domenech, A. et al., Isolation of salmon pancreas disease virus (SPDV) in cell culture and its ability to protect against infection by the 'wild-type' agent. Fish Shellfish Immunol. 2001, 11, 505-522.
77. Cho, M. S., Yee, H., Chan, S., Establishment of a human somatic hybrid cell line for recombinant protein production. J. Biomed. Sci. 2002, 9, 631-638.
78. Wiegant, J., Brouwer, K., Bezrookove, V., Smits, S. et al., Molecular cytogenetic characterization by combined COBRA-FISH and fiber-FISH: application to PER.C6 cells. Biotechniques 2004, 37, 180, 190, 192 passim.
79. Finch, C., Li, W., Perez, D. R., Design of alternative live attenuated influenza virus vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 205-235.
80. Liu, Y., Shin, H. D., Li, J., Liu, L., Toward metabolic engineering in the context of system biology and synthetic biology: advances and prospects. Appl. Microbiol. Biotechnol. 2015, 99, 1109-1118.
81. Jacobs, J. P., Jones, C. M., Baille, J. P., Characteristics of a human diploid cell designated MRC-5. Nature 1970, 227, 168-170.
82. Hayflick, L., The Limited in Vitro Lifetime of Human Diploid Cell Strains. Exp. Cell Res. 1965, 37, 614-636.
83. Lemckert, A. A., Grimbergen, J., Smits, S., Hartkoorn, E. et al., Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 2006, 87, 2891-2899.
84. Vellinga, J., Smith, J. P., Lipiec, A., Majhen, D. et al., Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum. Gene Ther. 2014, 25, 318-327.
85. Uytdehaag, A. G. C., Pau, M. G., Schouten, G., Production influenza virus vaccines. WO Patent 045674 A1, 2007.
86. Pau, M. G., Uytdehaag, A. G. C., Schouten, G., Production of vaccines. US Patent 0063261 A1, 2006.
87. Sanders, B. P., Edo-Matas, D., Custers, J. H., Koldijk, M. H. et al., PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine 2013, 31, 850-856.
88. Samina, I., Havenga, M., Koudstaal, W., Khinich, Y. et al., Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine 2007, 25, 8338-8345.
89. De Vocht, M. L., Backus, H. H. J., Van Corven, E. J. J., Lagerwerf, F. et al., Methods for the production of a whole-inactivated West Nile virus vaccine. WO Patent 122964 A1, 2006.
90. Lohr, V., Rath, A., Genzel, Y., Jordan, I. et al., New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27, 4975-4982.
91. Lohr, V., Genzel, Y., Jordan, I., Katinger, D. et al., Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. BMC Biotechnol. 2012, 12, 79.
92. Jordan, I., Sandig, V., Novel MVA virus and uses thereof. WO Patent 048500 A1, 2014.
93. Jordan, I., Sandig, V., Cell line for propagation of highly attenuated alphaviruses, US 2011/0229969 A1, 2011.
94. Meszaros, I., Toth, R., Balint, A., Dan, A. et al., Propagation of viruses infecting waterfowl on continuous cell lines of Muscovy duck (Cairina moschata) origin. Avian Pathol. 2014, 43, 379-386.